Phase 1 Interstitial Lung Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to provide written consent to participate.
• People who are older than 40 and younger than 90 years old at the time of signing the consent form.
• People who have been clinically diagnosed with interstitial lung disease (ILD) before the screening stage, based on established international guidelines.
• People whose lung function test results meet specific minimum thresholds — FVC at or above 45% of the predicted value, and DLCO at or above 30% (confirm with trial site for exact testing details).
• People whose blood oxygen level at rest is 92% or higher, while using no more than 3 litres per minute of supplemental oxygen.
• People whose right-sided heart pressure reading (RVSP) is below 50 mmHg, as confirmed by an ultrasound of the heart or a heart catheter procedure.
• Women who have either had a surgical procedure that prevents pregnancy or have been through menopause for more than one year.

Who may not be able to join:

• People whose CT scan or lung biopsy results do not match a diagnosis of IPF (a specific type of Ilung disease).
• People who are unable to complete the required study assessments, such as breathing tests, CT scans, blood draws, or written questionnaires.
• People who are currently taking, or have taken within the past four weeks, any medication, treatment, or experimental therapy for ILD — except for oxygen therapy or pulmonary rehabilitation.
• People who are currently listed, or expected to be listed in the future, for any organ transplant.
• People whose screening blood test results fall outside acceptable ranges, including low red blood cell levels, low white blood cell count, low platelet count, or abnormal liver or clotting markers (confirm with trial site for specific values).
• People with serious other health conditions that, in the treating doctor's judgement, could affect their safety or ability to complete the study — including but not limited to HIV, advanced liver or kidney failure, severe heart failure, recent heart attack, unstable chest pain, heart bypass surgery within the last six months, or severe airflow obstruction in the lungs.
• People with any other condition that, in the treating doctor's judgement, could affect safety or the ability to complete the study.
• People who have previously received an organ transplant.
• People who have had a cancer diagnosis within the past two and a half years — although people treated for certain skin cancers (basal cell, squamous cell) or cervical cancer may still be considered eligible (confirm with trial site).
• People with a non-lung condition that is expected to limit life expectancy to less than one year.
• People with a history of drug or alcohol misuse within the past 24 months.
• People whose blood tests show the presence of HIV, hepatitis B, or active hepatitis C infection.
• People who are currently participating, or have participated within the past 30 days, in another clinical trial of an investigational treatment or device.
• Women who are pregnant, breastfeeding, or capable of becoming pregnant and not using effective contraception. A pregnancy blood or urine test is required at screening and within 36 hours before any injection.
• Women whose FSH hormone level is 25.8 IU/L or higher (a hormone measurement related to reproductive status).
• People who have a known allergy or sensitivity to a substance called dimethyl sulfoxide (DMSO).
• People whose resting blood oxygen level is below 93% when breathing normal air at or near sea level, or below 88% when at elevations above 5,000 feet (approximately 1,524 metres).

Important: Always verify eligibility with the trial site directly before applying.